Proceeds from this financing will support continued clinical development of ataluren in Duchenne muscular dystrophy and cystic fibrosis. PTC is initiating a Phase 3 confirmatory trial of ataluren in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) with the goal of commencing enrollment in the first half of 2013.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

100 Corporate Ct.
South Plainfield, NJ 07080
USA

Phone

(908) 222-7000

Website

www.ptcbio.com

Email Address

[email protected]

Overview

PTC (NASDAQ; PTCT) is a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms.

Profile

Social Media

PTC Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Stuart Peltz

Chief Financial Officer

Christine Utter

Vice President

Mary Harmon

VP - General Counsel

Mark Boulding

VP - Human Resources

Martin Rexroad

VP - R & D

Neil Almstead

Browse more venture capital transactions:

Prev: 3/8/2013: Spaceport.io venture capital transaction
Next: 3/8/2013: Salesfusion venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary